Are music labels about to dictate the terms of Indian cinema? What began as strategic investments—Saregama's ₹325 crore stake in Sanjay Leela Bhansali Productions and Universal Music's acquisition of 30.8% in Excel Entertainment—has sparked questions about consolidation, control, and the future of India's entertainment ecosystem. In this episode of The Morning Brief, host Anirban Chowdhury speaks with ET’s film journalist Rajesh N Naidu and Nirmika Singh, founder of MOX Asia, former Editor, Rolling Stone India to decode the financial mechanics behind these deals.The discussion explores whether this signals industry consolidation or smart cost control, how music labels are securing IP at cheaper rates while expanding global reach, and what differentiated strategies—Universal's premium content scaling versus Saregama's long-haul domestic focus—reveal about competitive dynamics.

You can follow Anirban Chowdhury on his social media: X and Linkedin

Check out other interesting episodes like: How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

See omnystudio.com/listener for privacy information.

India's precious metals explosion defies gravity as equities stumble. While the Nifty crawls at 10.5% and bleeds 4% this year, gold has rocketed from $2,700 to over $5,000. Silver from $28 to $100. That's a 200% surge in twelve months. Geopolitical chaos, tariff wars, and safe-haven demand are fueling this unprecedented rally. In this episode, host Kairavi Lukka talks to Naveen Mathur, Director - Commodities & Currencies, Anand Rathi Share and Stock Brokers Ltd, who warns: gold remains your portfolio anchor, but silver's volatility demands caution. With targets eyeing $5,500 for gold and ₹3.45 lakh/kg for silver, the question isn't whether precious metals outshine stocks, but whether investors can stomach the wild swings ahead. The metals revolution is here.

You can follow Kairavi Lukka on his social media:X and Linkedin

Check out other interesting episodes like: When Grinch Almost Stole Gig Workers' Christmas, How Will a Volatile ₹ Impact You in 2026?, How Quick Commerce is Triggering a Health Crisis for Gen Z, India’s Labour Law Reboot, Viral to Valuation: Building Women’s Cricket as a Brand and much more.

Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

See omnystudio.com/listener for privacy information.

Qure.ai is transforming routine medical imaging into early disease detection at unprecedented scale. Processing nearly 1,000 patients per hour across 105 countries, the startup has made preliminary radiology reports at India’s AIIMS and CMC Vellore AI-powered often flagging diseases physicians weren’t even looking for. In this conversation, Vikas Dandekar speaks with Prashant Warier Co-founder & CEO, Ankit Modi, Founding Member and Chief Product Officer and Preetham Putha, Founding Member and Chief AI Officer about how Qure.ai is reimagining diagnostics. Their breakthrough includes risk-scoring algorithms that detect high-risk lung nodules on standard chest X-rays, achieving a 54% CT-confirmed malignancy rate. From TB screening programs in Mumbai. where their tools uncovered 35% more cases for lung cancer detection in US hospitals, Qure.ai now holds 19 FDA clearances and WHO endorsement for autonomous AI diagnosis. Founded in 2016 and trained on over 1.5 billion anonymized images, Qure.ai has published clinical evidence in The Lancet and Nature. With current revenues of ₹200 crore, the company is targeting profitability within two years while scaling toward its ambition of impacting 1 billion lives by 2030.

See omnystudio.com/listener for privacy information.